Lupin And DKSH To Market Five Alvotech Biosimilars In The Philippines
Reference Product Sales More Than $16bn In 2021
Lupin’s Multicare Pharmaceuticals subsidiary in the Philippines will partner with distributor DKSH to market five Alvotech biosimilars. Alvotech’s biosimilars, which remain at the pre-approval stages, reference Prolia/Xgeva, Eylea, Simponi, and two more undisclosed molecules.
You may also be interested in...
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
Lupin has celebrated the Canadian approval for its Rymti (etanercept) biosimilar, with all indications matching reference product Enbrel. The product represents the third version of Enbrel approved in Canada.